NOVACYT S.A. - Final Results

Novacyt S.A. delivered a resilient final results investor update, reporting 2025 revenue of £20m, with underlying growth of 4% after the Taiwan divestment, a strong 63% gross margin, and a reduced EBITDA loss of £7.8m. The molecular diagnostics group highlighted continued progress against its growth strategy, including increased R&D investment, IVDR-accredited product development, and new launches such as LightBench Discover, which helped drive 25% instrumentation growth. Clinical revenues represented around 70% of group sales, supported by double-digit growth in NIPT, contract wins in the UK, Iceland and Thailand, and expanding Asia-Pacific demand. Novacyt also strengthened its international footprint through the earnings-accretive acquisition of Southern Cross Diagnostics, enhancing access to the fast-growing Australian diagnostics market and supporting the pathway to EBITDA profitability. With £11m cash at March 2026, a streamlined cost base, upcoming DPYD assay launch, and a target of double-digit revenue growth, Novacyt is positioning for sustained commercial expansion, improved margins, and long-term shareholder value.